2011
DOI: 10.5867/medwave.2011.04.5012
|View full text |Cite
|
Sign up to set email alerts
|

Evaluación económica del dasatinib en el tratamiento de la leucemia mieloide crónica en pacientes resistentes al imatinib en Chile

Abstract: Estudio de evaluación económica. Al apreciar estos estudios hay que considerar varios aspectos. Esta publicación contiene elementos que debieran ser de interés para los lectores: ya en la sección métodos aporta un valioso análisis sobre la adaptabilidad en estos estudios, a propósito de los supuestos empleados en él. Utiliza QALYs como medida de efectividad, que es importante conocer, y su horizonte temporal es amplio (toda la vida del paciente), lo que por otra parte introduce incerteza. Elegante artículo que… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 37 publications
0
2
0
Order By: Relevance
“…Considering Figure 2, reference [3,24] was the most influential in the study. To show the results of the meta-analysis, the Forest plot is shown, where the correlation in Fisher's z-values and confidence intervals are indicated (Figure 3).…”
Section: Meta-analysis Resultsmentioning
confidence: 93%
See 1 more Smart Citation
“…Considering Figure 2, reference [3,24] was the most influential in the study. To show the results of the meta-analysis, the Forest plot is shown, where the correlation in Fisher's z-values and confidence intervals are indicated (Figure 3).…”
Section: Meta-analysis Resultsmentioning
confidence: 93%
“…One of the treatments that offers remission of the disease is bone marrow transplantation, which is available only for a minority of patients with very specific conditions, and the treatment depends on the availability of a donor [3]. It is, therefore, necessary to adequately 2 of 18 manage treatment to offer an opportunity to patients who do not have this treatment option to improve their clinical conditions against the disease.…”
Section: Introductionmentioning
confidence: 99%